Temporal (Giant Cell) Vasculitis

What is Vasculitis (Temporal)?

Temporal vasculitis, also called **giant cell arteritis (GCA)**, is an inflammatory disease that primarily affects the large‑ and medium‑sized arteries that supply blood to the head, especially the temporal arteries located above the ears. The inflammation can cause the arterial wall to thicken, narrow, and sometimes become occluded, leading to reduced blood flow to the eye, scalp, and brain. Although it most often occurs in adults over age 50, the condition can occasionally appear in younger individuals.

GCA is a type of systemic vasculitis, meaning it can affect vessels throughout the body, but the hallmark is the involvement of the cranial branches of the carotid artery. Prompt recognition is crucial because untreated GCA can cause irreversible vision loss, stroke, or even death.

Common Causes

The exact trigger for giant cell arteritis is unknown, but several risk factors and associated conditions increase the likelihood of developing the disease.

• Age: Incidence rises sharply after age 50, peaking in the 70s.
• Sex: Women are about three times more likely to develop GCA than men.
• Genetics: Certain HLA‑DRB1 alleles (e.g., HLA‑DR4) are linked with higher risk.
• Polymyalgia rheumatica (PMR): Up to 50 % of patients with GCA also have PMR, a condition causing shoulder and hip girdle pain.
• Autoimmune predisposition: A personal or family history of autoimmune diseases (e.g., rheumatoid arthritis, lupus).
• Infections: Some studies suggest prior viral or bacterial infections may act as a trigger, though evidence is not definitive.
• Smoking: Current or former smokers have a modestly increased risk.
• Geographic/ethnic factors: Higher prevalence in people of Northern European descent.
• Environmental exposures: Occupational exposure to dust, silica, or certain chemicals has been reported in case‑control series.
• Medications: Rarely, immune‑modulating drugs can unmask vasculitic processes.

Associated Symptoms

GCA often presents with a constellation of systemic and localized signs. Commonly reported symptoms include:

• New‑onset headache: Usually unilateral, throbbing, and located over the temples.
• Scalp tenderness: Touching the scalp can be painful, especially over the affected artery.
• Jaw claudication: Pain or fatigue while chewing, a highly specific sign for GCA.
• Vision changes: Blurred vision, double vision, transient visual loss (amaurosis fugax), or sudden permanent blindness.
• Polymyalgia rheumatica symptoms: Morning stiffness and aching in the shoulders, neck, and hips.
• Constitutional symptoms: Low‑grade fever, fatigue, weight loss, and night sweats.
• Arterial bruits: A whooshing sound heard over the temporal artery with a stethoscope.
• Dry eyes or mouth: Due to autonomic involvement.
• Neurologic signs (rare): Transient ischemic attacks or stroke‑like symptoms.

When to See a Doctor

Because GCA can cause rapid, irreversible vision loss, any of the following warrants immediate medical attention:

• Sudden, unexplained vision changes or loss in one or both eyes.
• Severe, new headache that does not improve with over‑the‑counter medication.
• Persistent scalp tenderness or a pulsating lump on the side of the head.
• Jaw pain while chewing that is new or worsening.
• Fever, weight loss, or night sweats in an older adult without an obvious cause.
• Any combination of the above symptoms in a person over 50 years old.

Prompt evaluation can prevent permanent complications.

Diagnosis

Diagnosing temporal vasculitis involves a blend of clinical suspicion, laboratory testing, imaging, and sometimes a tissue biopsy.

1. Clinical Assessment

• Detailed history focusing on headache characteristics, jaw claudication, visual symptoms, and constitutional complaints.
• Physical exam for temporal artery tenderness, decreased pulsation, or audible bruits.

2. Laboratory Tests

• Erythrocyte sedimentation rate (ESR): Usually markedly elevated (>50 mm/hr).
• C‑reactive protein (CRP): Often high and may be more sensitive than ESR.
• Complete blood count – typically shows mild anemia and a normal or high platelet count.
• Liver function tests – alkaline phosphatase may be mildly elevated.

3. Imaging

• Ultrasound of the temporal arteries: “Halo sign” (hypoechoic thickening) is a non‑invasive, rapid screening tool.
• High‑resolution MRI or CT angiography: Useful for visualizing larger vessels (e.g., aorta) when systemic involvement is suspected.
• Positron emission tomography (PET): Detects inflammation in the aorta and its branches in atypical cases.

4. Temporal Artery Biopsy (Gold Standard)

• A segment (1–2 cm) of the temporal artery is removed under local anesthesia.
• Pathology shows granulomatous inflammation with multinucleated giant cells and intimal hyperplasia.
• Because inflammation can be segmental, a negative biopsy does not completely rule out GCA; clinical judgment remains paramount.

Treatment Options

Rapid initiation of therapy is essential. Treatment strategy aims to control inflammation, preserve vision, and minimize side effects.

1. High‑Dose Glucocorticoids (First‑Line)

• Immediate oral prednisone: 40–60 mg daily (≈1 mg/kg) for most patients; higher doses (80–100 mg) for those with visual loss.
• Intravenous methylprednisolone (500–1000 mg daily for 3 days) is recommended when abrupt vision loss or neurological deficits are present.
• Symptoms usually improve within 24–48 hours; ESR/CRP should begin to fall.
• Gradual taper over 12–18 months reduces relapse risk while limiting steroid toxicity.

2. Steroid‑Sparing Agents

• Tocilizumab: An IL‑6 receptor antagonist approved by the FDA for GCA. Given subcutaneously (162 mg weekly) or IV, it allows lower prednisone doses and faster taper.
• Methotrexate: 10–25 mg weekly can modestly reduce steroid requirements, though evidence is less robust than for tocilizumab.
• Azathioprine or mycophenolate mofetil: Occasionally used in refractory cases.

3. Adjunctive Care

• Calcium & Vitamin D supplementation plus weight‑bearing exercise to mitigate steroid‑induced osteoporosis.
• Proton‑pump inhibitor or H2 blocker for gastric protection.
• Blood pressure monitoring and lipid profile checks, as steroids raise cardiovascular risk.
• Vaccinations (influenza, pneumococcal, COVID‑19) before starting high‑dose steroids when possible.

4. Home & Lifestyle Measures

• Maintain a balanced diet low in sodium and refined sugars to counteract steroid‑related weight gain and hyperglycemia.
• Engage in low‑impact aerobic activity (walking, swimming) as tolerated.
• Use cool compresses on the scalp if tenderness is severe.
• Keep a symptom diary (headache intensity, visual changes, jaw pain) to share with your physician during follow‑up.

Prevention Tips

Because the exact cause of GCA is unknown, primary prevention is limited. However, you can reduce risk and mitigate complications:

• Regular medical check‑ups: Annual exams after age 50, especially if you have a history of polymyalgia rheumatica or other autoimmune conditions.
• Control cardiovascular risk factors: Manage hypertension, diabetes, and cholesterol, which lower the burden on blood vessels.
• Avoid smoking: Smoking cessation improves overall vascular health.
• Promptly treat infections: While not proven, handling upper‑respiratory infections quickly may reduce potential triggers.
• Vaccinations: Staying up‑to‑date helps prevent infections that could theoretically precipitate vascular inflammation.

Emergency Warning Signs

Key Take‑aways

• Temporal (giant cell) vasculitis is an emergency‑type disease that mostly affects adults >50 years.
• Typical signs are new‑onset temporal headache, scalp tenderness, jaw claudication, and potential vision loss.
• Diagnosis relies on clinical suspicion, elevated ESR/CRP, temporal artery ultrasound, and often a biopsy.
• High‑dose glucocorticoids are the cornerstone of therapy; tocilizumab is now the preferred steroid‑sparing agent.
• Early treatment dramatically reduces the risk of permanent blindness and other serious outcomes.

For personalized advice, always discuss symptoms and treatment options with a rheumatologist or your primary‑care physician. The information above reflects current guidelines from the American College of Rheumatology, Mayo Clinic, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) as of 2024.